Inhibitor of fatty acid synthase (FAS) reducing food intake and body weight in mice. Exhibits irreversible slow-binding biphasic inactivation of FAS. Down regulates neuropeptide Y and Agouti-related protein expression. Has been proposed to activiate CPT-1 activity in liver and adipose tissue, leading to increased fatty acid oxidation and energy production. Shows significant in vivo antitumor activity in human breast cancer cells.Suppresses DNA replication and induces apoptosis. FAS inhibition by C75 leads to dramatic accumulation of the CDK inhibitor p27KIP1 from cytosol to cell nuclei.
DMSO (18 mg/ml)
Protect from light
A FAS inhibitor
Tissue, pathway, proteinase, peptidase, protease ,acrosin, lipoprotein, activator, caspase, trypsin, papain, esterase inhibitors are proteins or receptor ligands or receptor antagonists that bind to an enzyme receptor and decreases its activity. Since blocking an enzyme's activity can kill a pathogen or correct a metabolic imbalance, many drugs are enzyme inhibitors. Not all receptor antagonist that bind to enzymes are inhibitors; enzyme activator ligands or agonists bind to enzymes and increase their enzymatic activity, while enzyme substrates bind and are converted to products in the normal catalytic cycle of the enzyme.
FAS Inhibitor, C75
Fas (TNF receptor superfamily, member 6) suppressor, C75
Alternative to gene target
Fas (TNF receptor superfamily, member 6), ALPS1A and APO-1 and APT1 and CD95 and FAS1 and FASTM and TNFRSF6, FAS and IDBG-81669 and ENSG00000026103 and 355, identical protein binding, nuclei, Fas and IDBG-159577 and ENSMUSG00000024778 and 14102, FAS and IDBG-637356 and ENSBTAG00000010785 and 282488